Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 218,376,792 papers from all fields of science
Search
Sign In
Create Free Account
5-(4-phenylbutoxy)psoralen
Known as:
psora-4
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
1 relation
Broader (1)
Ficusin
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
Angiotensin II reduces the surface abundance of KV1.5 channels in arterial myocytes to stimulate vasoconstriction
Michael W. Kidd
,
Simon Bulley
,
J. Jaggar
Journal of Physiology
2017
Corpus ID: 3604350
Several different voltage‐dependent K+ (KV) channel isoforms are expressed in arterial smooth muscle cells (myocytes…
Expand
2016
2016
Contribution of KV1.5 Channel to Hydrogen Peroxide–Induced Human Arteriolar Dilation and Its Modulation by Coronary Artery Disease
Y. Nishijima
,
S. Cao
,
+6 authors
David X. Zhang
Circulation Research
2016
Corpus ID: 3355643
Rationale: Hydrogen peroxide (H2O2) regulates vascular tone in the human microcirculation under physiological and…
Expand
Highly Cited
2013
Highly Cited
2013
Side pockets provide the basis for a new mechanism of Kv channel–specific inhibition
Stefanie Marzian
,
P. Stansfeld
,
+8 authors
N. Decher
Nature Chemical Biology
2013
Corpus ID: 24467332
A Kv1 channel inhibitor and potential therapeutic lead achieves selectivity by binding both the conserved central cavity and…
Expand
2010
2010
Voltage-gated potassium channel Kv1.3 blocker as a potential treatment for rat anti-glomerular basement membrane glomerulonephritis.
T. Hyodo
,
T. Oda
,
+12 authors
H. Kumagai
AJP - Renal Physiology
2010
Corpus ID: 20478241
The voltage-gated potassium channel Kv1.3 has been recently identified as a molecular target that allows the selective…
Expand
2010
2010
Effector memory T lymphocytes in renal disease.
D. Mattson
AJP - Renal Physiology
2010
Corpus ID: 40178795
recent studies have demonstrated that the immune system plays an important pathophysiological role in diseases of the kidney and…
Expand
2009
2009
Loss of cerebrovascular Shaker-type K(+) channels: a shared vasodilator defect of genetic and renal hypertensive rats.
Ann A Tobin
,
Biny K. Joseph
,
+5 authors
Sung W. Rhee
American Journal of Physiology. Heart and…
2009
Corpus ID: 16852460
The cerebral arteries of hypertensive rats are depolarized and highly myogenic, suggesting a loss of K(+) channels in the…
Expand
Highly Cited
2006
Highly Cited
2006
Selective blockage of Kv1.3 and Kv3.1 channels increases neural progenitor cell proliferation
S. Liebau
,
C. Pröpper
,
+4 authors
O. Wittekindt
Journal of Neurochemistry
2006
Corpus ID: 18522813
The modulation of cell proliferation in neural progenitor cells (NPCs) is believed to play a role in neuronal regeneration…
Expand
Highly Cited
2005
Highly Cited
2005
Design of PAP-1, a Selective Small Molecule Kv1.3 Blocker, for the Suppression of Effector Memory T Cells in Autoimmune Diseases
Alexander Schmitz
,
Ananthakrishnan Sankaranarayanan
,
+4 authors
H. Wulff
Molecular Pharmacology
2005
Corpus ID: 6931552
The lymphocyte K+ channel Kv1.3 constitutes an attractive pharmacological target for the selective suppression of terminally…
Expand
2005
2005
5-(3-Phenylpropoxy)psoralen and 5-(4-phenylbutoxy)psoralen: mechanistic studies on phototoxicity.
C. W. Bode
,
W. Hänsel
Pharmazie
2005
Corpus ID: 9620477
5-(3-Phenylpropoxy)psoralen and 5-(4-phenylbutoxy)psoralen are blockers of the lymphocyte potassium channel Kv1.3 with EC50…
Expand
Highly Cited
2004
Highly Cited
2004
Kv1.3-blocking 5-phenylalkoxypsoralens: a new class of immunomodulators.
Julia Vennekamp
,
H. Wulff
,
+4 authors
G. Chandy
Molecular Pharmacology
2004
Corpus ID: 13067136
The lymphocyte potassium channel Kv1.3 is widely regarded as a promising new target for immunosuppression. To identify a potent…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE